Gene Editing: The Future of Genomic Medicine & Biotech Investing

Episode Summary

Executive Summary: The episode explores gene editing as a rapidly advancing, potentially curative biotechnology. Salvine Richter explains how CRISPR and next-gen tools could treat genetic diseases, with early focus on liver, eye, blood, and certain cancer indications. Discussion covers regulation, IP, pricing, ethical limits, AI integration, and why investor and pharma interest is accelerating.

Main Topics: What gene editing is and why it matters (Priority: 5/5): Gene editing is described as a precise, permanent way to modify the human genome, positioned as a transformative step toward genomic medicine and functional cures. Near-term therapeutic targets and applications (Priority: 5/5): The conversation highlights where gene editing is most likely to succeed first: liver, eye, blood disorders like sickle cell and beta-thalassemia, rare diseases such as TTR, and some oncology settings. CRISPR and next-generation gene-editing tools (Priority: 5/5): CRISPR-Cas9 is presented as the leading platform because it is adaptable and easy to use, but the discussion also points to base editing, prime editing, and gene writing as future advances. Regulation, approvals, and intellectual property (Priority: 4/5): The podcast covers regulatory milestones, including ex vivo therapies nearing filing/approval and evolving FDA/European guidance, plus the Harvard-MIT CRISPR IP ruling and its limited expected impact on innovation. Pricing and payer challenges (Priority: 5/5): A major concern is how to pay for one-time, high-cost functional cures, especially in the U.S. where patient payer churn complicates reimbursement and long-term value capture. Ethics, safety, and social boundaries (Priority: 4/5): The discussion distinguishes somatic editing from germline editing, emphasizing broad scientific opposition to heritable editing and the need to monitor off-target effects and benefit-risk balance. Investment, M&A, and AI convergence (Priority: 4/5): Strong VC funding, pharma partnerships, and acquisition activity are accelerating the field, while machine learning/AI may help identify targets, screen candidates, and improve manufacturing.

Key Arguments: Gene editing can make permanent, precise changes to the genome, making it potentially curative rather than merely disease-managing. The most realistic early wins are in simpler biological settings—especially liver, eye, blood disorders, and single-mutation diseases. Ex vivo editing has already shown strong proof-of-concept in sickle cell disease, beta-thalassemia, and cancer; in vivo editing is now moving forward with TTR as a lead example. CRISPR-Cas9 is central because it is a flexible, easy-to-use platform, but innovation is broadening beyond it to newer editing modalities. Regulatory clarity is improving; ex vivo programs are approaching filings/approvals, and agencies are setting expectations for long-term follow-up. The Harvard-MIT CRISPR IP ruling is unlikely to halt innovation because companies can license IP and the field is already evolving with new technologies. Pricing remains one of the biggest commercial obstacles because payers must absorb million-dollar one-time treatments and manage patient turnover. Gene editing’s ethical boundaries are clear in the near term: therapeutic somatic editing is acceptable, while germline editing is broadly opposed. AI/ML could increase productivity by helping identify targets and enabling faster screening and manufacturing workflows. Big Pharma is engaged, but many larger players are still deciding whether to build, buy, or partner as clinical and commercial validation evolves.

Data Points: Podcast recording date: Monday, March 21st, 2022 - Stated in the closing disclaimer Regulatory follow-up duration: 15 years - FDA/European guidance for long-term follow-up data in gene-editing therapies Number of companies partnered on ex vivo CRISPR-Cas9 therapy: 2 - Companies guiding to year-end regulatory filing Potential regulatory filing timing: Year-end this year - Guidance for ex vivo outside-the-body CRISPR-Cas9 therapy filings Potential approval timing: Next year - Expected timing if filings are successful Price point for some curative therapies: Over $1 million - Discussed as a challenge for payer adoption and reimbursement Primary cell types excluded from somatic editing: Egg and sperm cells - Used to distinguish somatic from germline editing

Pivotal Quotes: "gene editing is a versatile tool and it's capable of making permanent, precise edits to the human genome." — Salvine Richter: Definition of gene editing at the start of the discussion "we do view this as poised for rapid growth." — Salvine Richter: Outlook for the gene-editing industry and technology adoption "broad consensus among the scientific community that germline editing in humans should not be performed" — Salvine Richter: Ethical boundary around heritable human editing

Implications: Gene editing is moving from science to clinic, but adoption will depend on regulatory clarity, payer models, and continued technical progress. Investors should watch next-gen tools, while society must keep firm boundaries on germline editing.